Patient P-02216
Therapy response
Improving
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
51%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S11
- Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 80 ME-01 recommended — Monitoring Escalation ME-01
- Day 81 Patient accepted — Started ME-01 in the companion
- Day 83 GI symptom burden −36% vs expected — GI Support Protocol GI-04
- Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 89 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 69.
Primary contributors, last 14 days
- Inflammatory activity-7
- Nutritional resilience+6
- GI instability-5
- Treatment adherence+3
- Toxicity-3
What helped?
- GI Support Protocol GI-04Day 74Result: symptom burden −36%
- Monitoring Escalation ME-01Day 80Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
54%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 64% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
- Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 43
- WearableHRV 24 ms, trending down
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 36/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 84 bpm
- Wearable2,948 steps/day
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 2.4 · butyrate capacity 36/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 25 ms
- Sleep
- 6.5 h
- Steps
- 3,521
- Resting HR
- 84 bpm
Daily log: GI score 48, nutritional resilience 48, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.